The 10 most and least expensive states for healthcare consumers

Going by the price of being a patient, North Carolina and Hawaii bookend the other 48 states.

Which is to say that the Tar Heel State is the most expensive while the Aloha State is the most affordable.

That’s according to an analysis based on nine key metrics as conducted by Forbes Advisor. The authors drew most of their data from KFF, supplementing this with data from the CDC and Mental Health America.

The metrics rely heavily on health insurance premiums and deductibles for various demographics and employment statuses. Other metrics include rates of cost avoidance for physician visits and mental healthcare attention, along with rates of households struggling to pay for children’s medical care.

The list shows six of the 10 priciest states for healthcare are located in the South.

Meanwhile half of the 10 most frugal-friendly are concentrated in Pacific and Western parts of the country.

The state in which residents are most likely to skip doctor visits due to costs turns out to be Texas.

Here’s a look at the top and bottom of the list.

Most expensive states for healthcare:

  1. North Carolina (Avg. annual premium/deductible: $7,180/$4,062)
  2. South Dakota
  3. Nebraska
  4. Florida
  5. Texas
  6. South Carolina
  7. Arizona
  8. Georgia
  9. New Hampshire
  10. Louisiana

Most affordable states for healthcare:

  1. Hawaii (Avg. annual premium/deductible: $5,374/$3,115)
  2. Michigan
  3. Washington
  4. California
  5. Massachusetts
  6. Pennsylvania
  7. Nevada
  8. Washington, D.C.
  9. Oregon
  10. Kentucky

Forbes Advisor is a custom publishing operation. Along with independent editorial content, the present article offers links to sponsors’ sales pages.

Full list and article here.

 

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.